Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04801381 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia

Study acronym: WATER III
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 2023 to Jan 16, 2025v4 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 202
    • Study sites: 3 to 5
    • Study completion date: Dec 2028 to Oct 2029
  2. Primary completion date: Dec 2022 to Dec 2023
    • Study completion date: Dec 2027 to Dec 2028
    • Study sites revised (3)
    • Study description expanded, about 5 words
    v3
  3. Study sites: 2 to 3v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Comparative analysis of efficacy and safety of Aquablation (AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA) and transurethral laser enucleation as surgical therapy for benign prostatic hyperplasia with large prostates (80-180ml).
Trial Details
NCT Number NCT04801381
Lead Sponsor University of Bonn
Collaborators: PROCEPT BioRobotics
Conditions
(from sponsor)		 BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Enrollment 202 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov